NeuBase Therapeutics Current Ratio vs. Current Valuation
| NBSEDelisted Stock | USD 1.62 0.17 9.50% |
For NeuBase Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of NeuBase Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well NeuBase Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between NeuBase Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of NeuBase Therapeutics over time as well as its relative position and ranking within its peers.
NeuBase |
NeuBase Therapeutics Current Valuation vs. Current Ratio Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining NeuBase Therapeutics's current stock value. Our valuation model uses many indicators to compare NeuBase Therapeutics value to that of its competitors to determine the firm's financial worth. NeuBase Therapeutics is rated below average in current ratio category among its peers. It is rated below average in current valuation category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value NeuBase Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.NeuBase Current Valuation vs. Current Ratio
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
NeuBase Therapeutics |
| = | 7.53 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
NeuBase Therapeutics |
| = | (5.83 M) |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
NeuBase Current Valuation vs Competition
NeuBase Therapeutics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 2.83 Billion. NeuBase Therapeutics has negative current valuation of (5.83 Million) having no influence on the industry.
NeuBase Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in NeuBase Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, NeuBase Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of NeuBase Therapeutics' change in net profit over the period of time. It can combine multiple indicators of NeuBase Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania. Neu Base operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 33 people.
NeuBase Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on NeuBase Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of NeuBase Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the NeuBase Therapeutics' important profitability drivers and their relationship over time.
Use NeuBase Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeuBase Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeuBase Therapeutics will appreciate offsetting losses from the drop in the long position's value.NeuBase Therapeutics Pair Trading
NeuBase Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to NeuBase Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeuBase Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeuBase Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeuBase Therapeutics to buy it.
The correlation of NeuBase Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeuBase Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeuBase Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NeuBase Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your NeuBase Therapeutics position
In addition to having NeuBase Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Electrical Equipment Thematic Idea Now
Electrical Equipment
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Electrical Equipment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Electrical Equipment Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in NeuBase Stock
If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |